S. Mondot

552 total citations
14 papers, 475 citations indexed

About

S. Mondot is a scholar working on Physiology, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, S. Mondot has authored 14 papers receiving a total of 475 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Physiology, 5 papers in Molecular Biology and 5 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in S. Mondot's work include Nitric Oxide and Endothelin Effects (7 papers), Receptor Mechanisms and Signaling (4 papers) and Eicosanoids and Hypertension Pharmacology (3 papers). S. Mondot is often cited by papers focused on Nitric Oxide and Endothelin Effects (7 papers), Receptor Mechanisms and Signaling (4 papers) and Eicosanoids and Hypertension Pharmacology (3 papers). S. Mondot collaborates with scholars based in France. S. Mondot's co-authors include Icilio Cavero, M Mestre, J. Pratz, C Richer, Paul Mulder, Howard Lippton, A L Hyman, L Julou, Clint A. James and Bernard Terlain and has published in prestigious journals such as Journal of Pharmacology and Experimental Therapeutics, Biochemical Pharmacology and Molecular Pharmacology.

In The Last Decade

S. Mondot

14 papers receiving 438 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Mondot France 10 224 186 170 169 110 14 475
Linda Merkel United States 14 300 1.3× 162 0.9× 188 1.1× 69 0.4× 56 0.5× 25 551
Richard D. Rainbow United Kingdom 15 294 1.3× 118 0.6× 161 0.9× 141 0.8× 91 0.8× 34 555
Kengo Harada Japan 12 357 1.6× 81 0.4× 137 0.8× 120 0.7× 134 1.2× 24 558
J G Dobson United States 14 321 1.4× 91 0.5× 452 2.7× 230 1.4× 88 0.8× 17 766
Jasma Rucker United States 7 459 2.0× 116 0.6× 231 1.4× 177 1.0× 104 0.9× 8 737
B Lewartowski Poland 19 415 1.9× 126 0.7× 501 2.9× 81 0.5× 183 1.7× 70 858
Frances M. Ashcroft United Kingdom 14 592 2.6× 70 0.4× 132 0.8× 341 2.0× 166 1.5× 18 1.1k
Morio Kanno Japan 9 185 0.8× 228 1.2× 213 1.3× 82 0.5× 54 0.5× 13 457
Charles L. Hoppel United States 6 340 1.5× 154 0.8× 67 0.4× 90 0.5× 56 0.5× 7 505
Nicola Moro Italy 8 292 1.3× 126 0.7× 71 0.4× 84 0.5× 43 0.4× 9 492

Countries citing papers authored by S. Mondot

Since Specialization
Citations

This map shows the geographic impact of S. Mondot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Mondot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Mondot more than expected).

Fields of papers citing papers by S. Mondot

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Mondot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Mondot. The network helps show where S. Mondot may publish in the future.

Co-authorship network of co-authors of S. Mondot

This figure shows the co-authorship network connecting the top 25 collaborators of S. Mondot. A scholar is included among the top collaborators of S. Mondot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Mondot. S. Mondot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
2.
Pratz, J., et al.. (1991). Effects of the K+ channel activators, RP 52891, cromakalim and diazoxide, on the plasma insulin level, plasma renin activity and blood pressure in rats.. Journal of Pharmacology and Experimental Therapeutics. 258(1). 216–222. 40 indexed citations
3.
Cavero, Icilio, J. Pratz, & S. Mondot. (1991). K+ channel opening mediates the vasorelaxant effects of nicorandil in the intact vascular system.. PubMed. 80 Suppl 7. 35–41. 3 indexed citations
4.
Richer, C, et al.. (1990). Cardiovascular and biological effects of K+ channel openers, a class of drugs with vasorelaxant and cardioprotective properties. Life Sciences. 47(19). 1693–1705. 89 indexed citations
5.
Mondot, S., et al.. (1990). Hemodynamic and pharmacological evaluation of the vasodilator and vasoconstrictor effects of endothelin-1 in rats.. Journal of Pharmacology and Experimental Therapeutics. 252(1). 300–311. 48 indexed citations
6.
Mondot, S., M Mestre, & Icilio Cavero. (1990). K+ activation mediates systemic and regional vasorelaxant effects of RP 52891 and nicorandil. European Journal of Pharmacology. 183(4). 1326–1327. 2 indexed citations
7.
James, Clint A., et al.. (1990). 2-(3-Pyridyl)-tetrahydrothiopyran-2-carbothioamide derivatives and analogues: A novel family of potent potassium channel openers. Drugs of the Future. 15(11). 1097–1097. 32 indexed citations
8.
Cavero, Icilio, S. Mondot, & M Mestre. (1989). Vasorelaxant effects of cromakalim in rats are mediated by glibenclamide-sensitive potassium channels.. Journal of Pharmacology and Experimental Therapeutics. 248(3). 1261–1268. 134 indexed citations
9.
10.
Mondot, S. & Icilio Cavero. (1988). Cardiovascular profile of 59227 RP, a novel potent and specific PAF receptor antagonists. Prostaglandins. 35(5). 827–827. 3 indexed citations
11.
Mondot, S., et al.. (1988). Pharmacological profile of a novel potent and specific PAF receptor antagonist, the 59227 RP. Prostaglandins. 35(5). 838–838. 6 indexed citations
12.
Floch, Anne, et al.. (1987). Paf binding sites. Biochemical Pharmacology. 36(19). 3221–3229. 14 indexed citations
13.
Mondot, S., et al.. (1985). 48 740 R.P. : A specific paf-acether antagonist. Prostaglandins. 30(4). 688–688. 18 indexed citations
14.
Mondot, S., et al.. (1982). Hypotensive activity of PAF-acether in rats. Inflammation Research. 12(5). 725–730. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Linda Merkel Breakdown of academic impact, for papers by Richard D. Rainbow Breakdown of academic impact, for papers by Kengo Harada Breakdown of academic impact, for papers by J G Dobson Breakdown of academic impact, for papers by Jasma Rucker Breakdown of academic impact, for papers by B Lewartowski Breakdown of academic impact, for papers by Frances M. Ashcroft Breakdown of academic impact, for papers by Morio Kanno Breakdown of academic impact, for papers by Charles L. Hoppel Breakdown of academic impact, for papers by Nicola Moro
Rankless by CCL
2026